Drug Candidate for the Treatment of Glioblastoma

Dear Colleagues,

Glioblastoma multiforme (GBM) is a lethal central nervous system malignancy with a median patient survival of a few months. Currently, due to complex signaling pathway activation, there is no cure for GBM, and the first-line drug temozolomide (TMZ) can only prolong the life expectancy of treated patients. Therefore, the combined treatment of surgery and radiation therapy and Innovative treatment options seems to be an interesting approach for treating GBM. Innovative therapeutic strategies are still critically in need. Cancer vaccine and new drug is an attractive option as it aims to induce a durable response or therapeutic relevance to eradicate GBM.

We welcome articles on the development of new pharmacologically active compounds and the continued use of natural products, synthetic and existing drugs as new drug developments for the treatment of GBM.  We welcome your review and original articles that shed light on the challenges and opportunities in the development of GBM treatment drugs. Topics include: new positioning of GBM treatment drugs, selective optimization and reduction of side effects, and the origin and application of synthetic drugs or drug metabolites as new drugs, drug delivery system, nanomaterial applications. The collection of manuscripts will be published as a special issue of the journal.

Prof. Dr. Yi-Chiang Hsu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Glioblastoma multiforme
• tumor antigens
• metastasis
• vaccine
• nanotechnology